Live Breaking News & Updates on Apex laboratories private

Stay informed with the latest breaking news from Apex laboratories private on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Apex laboratories private and stay connected to the pulse of your community

ITAT Confirms Addition of Expenses Incurred On Brand Reminders, Customer Gifts For Doctor

The Mumbai Bench of Income Tax Appellate Tribunal (ITAT) has confirmed the addition towards expenses incurred on brand reminders, customer gifts, and the purchase of medical books and journals for...

Mumbai , Maharashtra , India , Indian-medical-council , Supreme-court , Apex-laboratories-private , Mumbai-bench , Income-tax-appellate-tribunal , Rahul-chaudhary , Judicial-member , Prashant-maharishi

Antiviral drug 'Clevira' repurposed for treatment of mild to moderate COVID-19 cases

Antiviral drug 'Clevira' repurposed for treatment of mild to moderate COVID-19 cases
Photo: Pexels
Clevira, a drug primarily developed to treat dengue, has been repurposed as supportive treatment for mild to moderate COVID-19 cases, its manufacturer Apex Laboratories Private Limited said on Friday.
The drug is effective when taken orally and the dosage is one tablet twice daily after food for 14 days. The drug has also proved to be safe on liver and kidney parameters, it said.
"Clevira, an antiviral formulation, has received regulatory approval as a supportive treatment for mild to moderate COVID-19 cases," the Chennai-based pharmaceutical company said.

India , Chennai , Tamil-nadu , C-arthur-paul , International-business , Indian-council-for-medical-research , Apex-laboratories-private , Ayurvedic-sciences , Interdisciplinary-technical-review-committee , Central-council-for-research , Government-medical-college-omandurar , Apex-laboratories-private-limited

Antiviral drug 'Clevira' repurposed for treating mild to moderate Covid-19 patients | India News

India News: NEW DELHI: Clevira, a drug primarily developed to treat dengue, has been repurposed as supportive treatment for mild to moderate Covid-19 cases, its m.

India , Chennai , Tamil-nadu , C-arthur-paul , International-business , Indian-council-for-medical-research , Apex-laboratories-private , Ayurvedic-sciences , Interdisciplinary-technical-review-committee , Central-council-for-research , Government-medical-college-omandurar , Apex-laboratories-private-limited

Antiviral drug Clevira repurposed for treating mild to moderate COVID-19 cases

New Delhi: Clevira, a drug primarily developed to treat dengue, has been repurposed as a supportive treatment for mild to moderate COVID-19 cases, its

India , New-delhi , Delhi , Chennai , Tamil-nadu , C-arthur-paul , International-business , Indian-council-for-medical-research , Apex-laboratories-private , Ayurvedic-sciences , Interdisciplinary-technical-review-committee , Central-council-for-research

Clevira, an antiviral formulation received Government of India regulatory approval as a supportive treatment for mild to moderate COVID-19 cases

Share
Bhubaneswar: Apex Laboratories Private Limited, a Chennai based pharmaceutical company known for its cutting-edge research and innovation, introduces Clevira, an antiviral herbal formulation.
Clevira was developed primarily to treat dengue patients in 2017. Last year as the COVID-19 cases surged in the country, it was repurposed as supportive treatment for mild to moderate COVID symptoms. The product is available across India and is priced at Rs 11 per tablet.
A clinical trial was conducted on 100 people in May-June 2020 and the results were promising.
During the 30 days trial, conducted at Government Medical College, Omandurar Government Estate Chennai, after approval from the Tamil Nadu government, the selected 100 participants were randomized into 2 Groups with 50 patients in each: the control group comprised of patients diagnosed with SARS-CoV-2 infection received standard care treatment as per hospital regulation as well as the WHO/ICMR guidelines. The test group patients with SARS-CoV-2 infection received, along with standard care treatment (as per hospital regulation and the WHO/ICMR guidelines) Clevira tablets twice daily orally after food for 14 days. It was found that Clevira significantly reduced the time taken for clinical recovery, which was noted in terms of reduction in pyrexia or body pain, normalisation of the respiratory rate ( less than 24/minute), improvement in oxygen saturation level ( more than 94%), etc.

Bhubaneswar , Orissa , India , Chennai , Tamil-nadu , Karthik-shanmugam , C-arthur-paul , Pvt-ltd , Apex-laboratories-pvt-ltd , Indian-council-of-medical-research , Government-medical-college , International-business

Antiviral drug 'Clevira' repurposed for treating mild to moderate COVID-19 patients

Antiviral drug 'Clevira' repurposed for treating mild to moderate COVID-19 patients
The drug is effective when taken orally and the dosage is one tablet twice daily after food for 14 days.
Share Via Email
| A+A A-
Beds lie inside an indoor stadium converted into COVID-19 treatment center for emergencies in the wake of the spike in the numbers of positive coronavirus cases in Srinagar. (Photo | AP)
By PTI
NEW DELHI: Clevira, a drug primarily developed to treat dengue, has been repurposed as supportive treatment for mild to moderate COVID-19 cases, its manufacturer Apex Laboratories Private Limited said on Friday.
The drug is effective when taken orally and the dosage is one tablet twice daily after food for 14 days.

India , Chennai , Tamil-nadu , C-arthur-paul , International-business , Indian-council-for-medical-research , Apex-laboratories-private , Ayurvedic-sciences , Interdisciplinary-technical-review-committee , Central-council-for-research , Government-medical-college-omandurar , Apex-laboratories-private-limited